PTS and cancer: These two classes of enzymes can be exploited to modify cellular behavior for therapeutic purposes (2); however, while several PTK inhibitors are in use in the clinic for indications such as cancer and inflammatory diseases (3), targeting of PTPs lags far behind (4), with the first chemical inhibitors only recently entering clinical trials (5, 6, 7, 8, 9).